

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claim 1. (Currently Amended) A method of ~~early diagnosing~~ assessing the risk of chronic rejection (CR) in a kidney transplanted human test subject, comprising:

a) assaying as a baseline value the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NOs:29, 30, 31, 32, 33, 34, 35, 36, 37, and 38~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722, EST ID 32f4, hoxA7 and PRLR in a renal allograft tissue biopsy obtained from a kidney transplanted human control subject who is known not to develop CR;

b) assaying as a test value the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NOs:29, 30, 31, 32, 33, 34, 35, 36, 37, and 38~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722, EST ID 32f4, hoxA7 and PRLR in a renal allograft tissue biopsy obtained from a kidney transplanted human test subject within the first year post-transplantation; and

c) comparing the baseline value of step a) with the test value of step b), wherein a baseline value lower than the test value, in the case of the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NO:29, 30, 31, 32, 33, 34, 35 or 36~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722 and EST ID 32f4, and higher than the test value, in the case of the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NO:37 or 38~~ hoxA7 and PRLR predicts that the kidney transplanted human test subject has an increased risk of developing CR.

Claim 2. (Currently Amended) The method according to claim 1, wherein renal allograft tissue biopsy of the transplanted human control subject is obtained from the control subject at the day of transplantation.

Claim 3. (Currently Amended) A method for monitoring CR in a kidney transplanted human subject at risk of developing CR, comprising:

a) assaying the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722, EST ID 32f4, hoxA7 and PRLR, in a renal allograft tissue biopsy sample obtained from a kidney transplanted human subject prior to exposure to transplant therapy;

b) assaying the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722, EST ID 32f4, hoxA7 and PRLR, in at least one renal allograft tissue biopsy sample obtained from the kidney transplanted human subject after exposure to transplant therapy; and

c) comparing the levels of expression detected in step a) and step b), wherein an increase in the levels detected in step b) in comparison to the levels detected in step a) in the case of the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35 and 36~~ KRT15, hoxB7, NPRL2, OS9, G-protein  $\gamma$  7, OBCML, DKFZp5586B1722, and EST ID 32f4 and a decrease in the levels detected in step b) in comparison to the levels detected in step a) in the case of the levels of nucleic acid expression of ~~the nucleic acid sequences set forth in SEQ ID NO: 37 and 38~~ hoxA7 and PRLR indicates an increased likelihood of developing CR.

Claims 4-14. (Canceled).

Claim 15. (Currently Amended) The method of claim 1, wherein the renal allograft tissue biopsy obtained from the kidney transplanted human test subject in step b) is obtained within 4 to 7 months post-transplantation.

Claim 16. (Currently Amended) The method of claim 15, wherein the renal allograft tissue biopsy obtained from the kidney transplanted human test subject in step b) is obtained at about 6 months post-transplantation.

Claim 17. (Currently Amended) The method of claim 3, wherein the at least one renal allograft tissue biopsy sample obtained from the kidney transplanted human subject in step b) is obtained within 4 to 7 months post-transplantation.

Claim 18. (Currently Amended) The method of claim 17, wherein the at least one renal allograft tissue biopsy sample obtained from the kidney transplanted human subject in step b) is obtained at about 6 months post-transplantation.